Table 2.

Prognostic Study Characteristics

Author Year	Number (n)	Deaths (n)	Follow-up (mo)	Amyloid Type	Cardiac Validati on	Age	Male (%)	EF (%)	NYH A Class >2 (%)	Modality	LGE Criteria	T1 Cutoff (ms)	ECV Cutoff
Wan19 2019	77	46	28[14–38]	AL	CMR, Echo	50±10	66	48±14	45	T1, ECV	-	1394*	0.442*
Ridouani20 2018	42	18	27[14–40]	AL, ATTR	Biopsy, Nuclear	69±13	70	54±15	50	ECV	-	-	0.590
Kotecha21 2018	100	28	23±15	AL	CMR	64±11	61	65±11	15	ECV	-	-	0.45*
Illman22 2018	76	52	20[NP]	AL	CMR	60±10	67	58±13	29	LGE	Global	-	-
Wan23 2018	78	54	38[27–46]	AL	CMR, Echo	59±11	60	50±12	-	LGE	Transmural	-	-
Martinez-Naharro3 2018	227	95	32±17	ATTR	Biopsy, Clinical, Nuclear	72±11	82	56±1 4	-	T1, ECV	-	1065*	0.525*
Lin24 2018	82	21	8[NP]	AL	-	56±9	63	63±15	34	LGE, ECV	Global	-	0.440
Ochs25 2017	68	44†	14[4–49]	AL	Biopsy	58±10	59	57±12	>50	LGE	Transmural	-	-
Baroni26 2017	42	31	37[10–50]	AL, ATTR	Suspected	57±12	74	56±11	-	LGE	Typical	-	-
Bhatti6 2016	251	97	28[5–56]	AL	Suspected	63[56–69]	64	61[51–68]	-	LGE	Typical	-	-
Fontana27 2015	250	67	24±13	AL,ATTR	Biopsy, Nuclear	67±12	68	60±14	-	LGE	Transmural	-	-
Banypersad28 2014	100	25	23 [NP]	AL	-	62±10	67	66±11	15	T1, ECV	-	1044	0.450
White9 2014	90	50	29[12–44]	AL, ATTR	Suspected	62±13	58	56[47–65]	>50	LGE	Global	-	-

Dichotomous variables are presented as percentages and continuous variables as mean ± standard deviation or median [interquartile range].

^*Cutoff was calculated based on high and low cardiac disease groups as prespecified by the study.

^†Reported as heart transplantation or death.

Superscript number references the study as listed in the Appendix 1.

AL=light chain amyloidosis, ATTR=transthyretin amyloidosis, CMR=cardiac magnetic resonance, Echo=echocardiography, ECV=extracellular volume mapping, LGE=late gadolinium enhancement, n=number, NP=not provided, mo=months, ms=milliseconds, T1=native T1 mapping.